News

The Ultragenyx offer represents a premium of over 358% to Dimension's unaffected share price as of August 24, 2017 and premiums of 24% and 48% over the implied

The cancer drug was evaluated in the late-stage study dubbed MURANO in combination with MabThera/Rituxan (rituximab) in CLL patients whose disease had relapsed or is in the refractory

The company signed two sale agreements to generate total proceeds of $2.48bn. Under the first deal, CVC Capital Partners Fund VI will acquire Teva’s women’s health product portfolio across contraception, fertility,

Proposed to have a brand name of Trelegy Ellipta, FF/UMEC/VI has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP) in

The decision of the European Commission on the approval is expected in the fourth quarter of 2017. “The recommendation by the CHMP for Cyltezo® is an important milestone

Mustang has entered into an exclusive, worldwide licensing agreement with Fred Hutchinson Cancer Research Center (“Fred Hutch”) for the use of a CAR T therapy related to autologous

Exenatide once-weekly did not increase the incidence of major adverse cardiovascular events (MACE), a composite endpoint of CV death, non-fatal heart attack (myocardial infarction) or non-fatal stroke, compared

Tradipitant was shown to improve the intensity of the worst itch patients experienced, as well as atopic dermatitis disease severity. Atopic dermatitis is a very common skin disorder

Under the deal, BMS will use Halozyme’s Enhanze drug-delivery technology to develop subcutaneously administered immuno-oncology medicines. Enhanze technology is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20),